Opioid Use Disorders Market to Reach US$ 8.8 Bn by 2034 as Overdose Prevention and Treatment Access Accelerate Growth | Latest Report TMR
Valued at US$ 3.2 Bn in 2023, the market is projected to reach US$ 8.8 Bn by 2034, advancing at a CAGR of 9.9% during 2024-2034.
The global opioid use disorders market is entering a period of strong expansion as healthcare systems, governments, and non-government organizations intensify efforts to address opioid addiction and overdose. Valued at US$ 3.2 Bn in 2023, the market is projected to reach US$ 8.8 Bn by 2034, advancing at a CAGR of 9.9% during 2024-2034.
đŸ‘‰ Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=75167
The market encompasses medicines and treatment solutions used to manage opioid use disorder (OUD), including buprenorphine, methadone, and naltrexone. Growing dependence on opioids, increasing awareness of treatment options, and greater investment in overdose prevention are creating sustained demand for effective therapies.
Market Overview
Opioid use disorder remains a significant global health challenge, with serious consequences for individuals, families, and healthcare systems. Medication-assisted treatment has become an important component of OUD management, with buprenorphine, methadone, and naltrexone among the principal therapeutic options.
The wider opioid crisis has also contributed to blood-borne infections and serious bacterial infections, including endocarditis, increasing the need for comprehensive treatment and harm-reduction strategies.
According to the World Health Organization, nearly 296 million people worldwide used drugs at least once during 2021, while about 39.5 million were living with drug disorders. In India, the National Drug Dependence Treatment Centre estimated opioid use at 2.1%, with approximately 0.6% of the population expected to require help for opioid-related problems.
Key Drivers of Market Growth
Rising Incidence of Opioid Addiction
The increasing prevalence of opioid dependence is the primary growth driver. Greater exposure to prescription and illicit opioids has increased demand for therapies capable of reducing dependence, withdrawal symptoms, cravings, and overdose risks.
Growing recognition of OUD as a treatable medical condition is also encouraging more patients to seek professional care, expanding the addressable treatment population.
Government and Non-Government Initiatives
Governments and non-government organizations are investing heavily in awareness, prevention, treatment access, and overdose-response programs. In August 2022, the U.S. Department of Health and Human Services announced US$ 79.1 Mn in overdose prevention grants.
Such initiatives are improving access to medication-assisted treatment while encouraging public awareness about opioid misuse. Continued funding is expected to remain an important market catalyst through 2034.
Increasing Focus on Harm Reduction
The growing use of naloxone for emergency treatment of suspected or known opioid overdose is strengthening the harm-reduction segment. Manufacturers are also exploring naloxone nasal sprays as accessible emergency interventions.
Meanwhile, companies are increasing production of buprenorphine hydrochloride and naloxone hydrochloride sublingual tablets, including generic alternatives to established combination treatments.
Key Players and Industry Leaders
Competition is shaped by product development, regulatory approvals, generic competition, patent strategies, and expanded treatment access. Major companies operating in the market include Indivior PLC, Alkermes plc, Orexo AB, Titan Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International, Inc., Viatris Inc., Hikma Pharmaceuticals plc, and Camurus AB.
Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/opioid-use-disorder-market.html
Market Segmentation
By Drug Type: Buprenorphine, Methadone, and Naltrexone.
By Route of Administration: Oral and Parenteral.
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
By Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Countries covered include the U.S., Canada, Germany, the U.K., France, Italy, Spain, China, India, Japan, Australia & New Zealand, Brazil, Mexico, South Africa, and GCC countries.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Comments
0 comment